Literature DB >> 9796701

Homozygous deletions at 3p12 in breast and lung cancer.

V Sundaresan1, G Chung, A Heppell-Parton, J Xiong, C Grundy, I Roberts, L James, A Cahn, A Bench, J Douglas, J Minna, Y Sekido, M Lerman, F Latif, J Bergh, H Li, N Lowe, D Ogilvie, P Rabbitts.   

Abstract

We have constructed a physical map of the region homozygously deleted in the U2020 cell line at 3p12, including the location of putative CpG islands. Adjacent to one of these islands, we have identified and cloned a new gene (DUTT1) and used probes from this gene to detect two other homozygous deletions occurring in lung and breast carcinomas: the smallest deletion is within the gene itself and would result in a truncated protein. The DUTT1 gene is a member of the neural cell adhesion molecule family, although its widespread expression suggests it plays a less specialized role compared to other members of the family.

Entities:  

Mesh:

Year:  1998        PMID: 9796701     DOI: 10.1038/sj.onc.1202103

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  35 in total

1.  Differential deletions of chromosome 3p are associated with the development of uterine cervical carcinoma in Indian patients.

Authors:  S Dasgupta; S B Chakraborty; A Roy; S Roychowdhury; C K Panda
Journal:  Mol Pathol       Date:  2003-10

2.  Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification.

Authors:  J Guillermo Paez; Ming Lin; Rameen Beroukhim; Jeffrey C Lee; Xiaojun Zhao; Daniel J Richter; Stacey Gabriel; Paula Herman; Hidefumi Sasaki; David Altshuler; Cheng Li; Matthew Meyerson; William R Sellers
Journal:  Nucleic Acids Res       Date:  2004-05-18       Impact factor: 16.971

3.  High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss.

Authors:  A Maitra; I I Wistuba; C Washington; A K Virmani; R Ashfaq; S Milchgrub; A F Gazdar; J D Minna
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 4.  Slit-Robo interactions during cortical development.

Authors:  William D Andrews; Melissa Barber; John G Parnavelas
Journal:  J Anat       Date:  2007-06-06       Impact factor: 2.610

Review 5.  Navigating breast cancer: axon guidance molecules as breast cancer tumor suppressors and oncogenes.

Authors:  Gwyndolen C Harburg; Lindsay Hinck
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-08-05       Impact factor: 2.673

6.  Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via blocking PI3K/Akt/β-catenin pathway.

Authors:  Po-Hao Chang; Wendy W Hwang-Verslues; Yi-Cheng Chang; Chun-Chin Chen; Michael Hsiao; Yung-Ming Jeng; King-Jen Chang; Eva Y-H P Lee; Jin-Yuh Shew; Wen-Hwa Lee
Journal:  Cancer Res       Date:  2012-07-23       Impact factor: 12.701

7.  Robo1 modulates proliferation and neurogenesis in the developing neocortex.

Authors:  Mason L Yeh; Yuko Gonda; Mathilda T M Mommersteeg; Melissa Barber; Athena R Ypsilanti; Carina Hanashima; John G Parnavelas; William D Andrews
Journal:  J Neurosci       Date:  2014-04-16       Impact factor: 6.167

8.  Coincidence of synteny breakpoints with malignancy-related deletions on human chromosome 3.

Authors:  Maria Kost-Alimova; Hajnalka Kiss; Ludmila Fedorova; Ying Yang; Jan P Dumanski; George Klein; Stefan Imreh
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-08       Impact factor: 11.205

9.  Deubiquitinating enzyme USP33/VDU1 is required for Slit signaling in inhibiting breast cancer cell migration.

Authors:  Junichi Yuasa-Kawada; Mariko Kinoshita-Kawada; Yi Rao; Jane Y Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

Review 10.  Semaphorins and their receptors in lung cancer.

Authors:  Vincent A Potiron; Joëlle Roche; Harry A Drabkin
Journal:  Cancer Lett       Date:  2008-07-14       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.